The antimicrotubule anticancer drug, Taxol, suppresses microtubule dynamics, causes mitotic arrest, and induces caspase-3 cleavage and activity resulting in apoptosis of human AML HL-60 cells. Caspase-3 cleavage is triggered by the mitochondrial release and cytosolic accumulation of the electron transfer protein, cytochrome c (cyt c). Taxol 
Introduction
Taxol (Paclitaxel) is an active antimicrotubule agent that has a broad spectrum of clinical activity against human cancers.
1,2
Following intracellular uptake, Taxol binds to ␤-tubulin and suppresses microtubular dynamics resulting in stable microtubule bundles and mitotic arrest of cells. [3] [4] [5] [6] Taxol-induced G2/M arrest is preceded by the activation of the cell-cycle mitotic kinase CDK1 (p34 cdc2 ) which promotes the G2/M transition. [7] [8] [9] CDK1 is a highly regulated serine-threonine kinase which in S and G2 phases is completed with its regulatory subunit cyclin B and phosphorylated at Thr 161 by a CDK1 activating kinase (CAK). 8, 9 During G2, cyclin B-CDK1 complex is kept inactive through phosphorylation of Tyr 15 and Thr 14 residues of CDK1. [8] [9] [10] Dephosphorylation of CDK1 at Tyr 15 and Thr 14 is catalyzed by cdc25 phosphatase at the G2/M boundary which initiates mitosis. [8] [9] [10] CDK1 activation controls G2/M transition by promoting nuclear membrane breakdown, chromatin condensation and microtubule spindle formation. [8] [9] [10] The cyclin B-CDK1 mitotic kinase is inactivated at the metaphase-anaphase transition by the degradation of cyclin B and disassembly of cyclin B-CDK1 complex, resulting in the cell exiting from mitosis. [8] [9] [10] In a previous report we demonstrated that Taxol-induced mitotic arrest of human AML HL-60 cells is associated with the cleavage and activity of caspase-3 (CPP32/Yama), degradation of poly(ADP-ribose) polymerase (PARP) and lamin B1, as well as the morphologic features and DNA fragmentation of apoptosis. 11 Overexpression of the antiapoptotic Bcl-2 or Bcl-x L proteins blocks caspase-3 activation and apoptosis without affecting Taxol-induced microtubule bundling and mitotic arrest. 12, 13 Recent reports have shown that cleavage and activation of caspase-3 is triggered by the mitochondrial release and cytosolic accumulation of the electron transfer protein cytochrome c (cyt c). 14, 15 However, whether Taxol induces the cytosolic accumulation of cyt c prior to caspase-3 activation and apoptosis has not been reported. The location of Bcl-2 and Bcl-x L in the outer mitochondrial membrane and their three-dimensional structure homology with the poreforming domains of bacterial toxins that function as membrane channel proteins are also consistent with the recent findings that Bcl-2 or Bcl-x L overexpression blocks the cytosolic accumulation of cyt c responsible for the cleavage and activity of caspase-3. [15] [16] [17] [18] Previous reports also suggested that some forms of apoptosis may be triggered by a premature and unscheduled activation of CDK1, while apoptotic DNA fragmentation and nuclear collapse could be prevented by blocking CDK1 activity. [19] [20] [21] Taken together, these reports raise the important issue of the temporal relationship of Taxol-induced CDK1 activation and G2/M transition to the increase in cytosolic cyt c triggering caspase-3 activity and apoptosis. The results of the present studies demonstrate that Taxol-induced CDK1 histone H1 kinase activity precedes its tyrosine dephosphorylation and G2/M transition. These events precede caspase-3 cleavage and activation promoted by cytosolic increase of cyt c. Additionally, Taxol-induced CDK1 activation and G2/M transition are not affected by either Bcl-x L overexpression or caspase inhibition, which inhibit the pre-apoptotic cytosolic accumulation of cyt c and caspase activation, respectively.
Materials and methods

Reagents
Taxol was kindly provided free of charge by Dr Patricia A Pilia of NaPro Bio-Therapeutics (Boulder, CO, USA). Taxol was made fresh for each experiment, as described previously. 6 The tetrapeptide caspase inhibitor Ac-YVAD-cmk and zVAD-fmk were purchased from Bachem (Torrance, CA, USA). Dr Ron Jemmerson of the University of Minnesota Medical School (Minneapolis, MN) kindly provided the monoclonal antibody to cyt c.
14 Anti-caspase-3 antibody was purchased from Transduction Laboratories (Lexington, KY, USA), whereas a polyclonal PARP antibody was kindly provided by Dr Ernest Kun of San Francisco State University (Tiburon, CA, USA). 22 Antibodies for detection of tyrosine phosphorylation of CDK1 were purchased from New England Biolabs (Beverly, MA, USA), whereas anti-cyclin B1 antibodies were purchased from DAKO (Carpinteria, CA, USA).
Cells and transfection of the bcl-x L gene
Human acute myeloid leukemia HL-60/neo and HL-60/Bcl-x L cells were created and passaged twice per week as previously described. 11 Logarithmically growing cells were used for the studies described below.
Western analyses of proteins
The expression of CDK1, p32 pro-caspase-3, PARP and cyclin B1 proteins in untreated and Taxol-treated HL-60/neo or HL-60/Bcl-x L cells were determined by Western blot analyses according to a previously described method. 6, 11, 23 Briefly, protein was extracted from cells with lysis buffer (142.5 mM KCl, 5 mM MgCl 2 , 10 mM Hepes (pH 7.2), 1 mM EGTA, 0.2% NP40, and 0.2 mM phenylmethylsulfonyl fluoride) supplemented with 0.2 trypsin inhibitory units/ml aprotinin, 0.7 g/ml pepstatin, and 1 g/ml leupeptin. Appropriate protein amounts (20 g) were subjected to SDS-PAGE (10% gel). After electrophoresis, proteins were transferred to nitrocellulose sheets (0.5 A at 100 V; 4°C) for 1-3 h. The blots were blocked in 5% nonfat dry milk solution for 3 h at room temperature with gentle shaking (5% nonfat milk (w/v)/PBS/0.02% sodium azide (pH 7.4)). This was followed by incubation with the respective antibody (1:1000 dilution) at room temperature and then with anti-rabbit or anti-mouse peroxidaseconjugated secondary IgG antibodies. Immune complexes were detected with an enhanced chemiluminescence detection method by immersing the blot for 1 min in a 1:1 mixture of chemiluminescence reagents A and B (Amersham International, Buckinghamshire, UK) and then exposing to Kodak X-OMAT film (Eastman Kodak Company, Rochester, NY, USA) for a few seconds. Horizontal scanning densitometry was performed on Western blots by utilizing acquisition into Adobe Photo Shop (Apple, Cupertino, CA, USA) and analysis by the NIH Image Program. The expression of ␤-actin was used as a control.
Preparation of S-100 fraction and Western analysis for cytochrome C
Untreated and drug-treated cells were harvested by centrifugation at 1000 g for 10 min at 4°C. The cell pellets were washed once with ice-cold PBS and resuspended with five volumes of buffer (20 mM Hepes-KOH, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol, and 0.1 mM PMSF), containing 250 mM sucrose. The cells were homogenized with a 22-gauge needle, and the homogenates were centrifuged at 100 000 g for 15 min at 4°C (S-100 fraction). The supernatants were collected, and the protein concentrations of S-100 were determined by Bradford method (Bio-Rad, Hercules, CA, USA). Twenty to 30 g of S-100 was used for Western blot analysis of cyt c, as described previously. 6, 11, 23 p34 cdc-2 kinase assay
Whole cell extracts were prepared by lysis of PBS-washed cell pellets in lysis buffer containing KCl 142.5 mM, MgCl 2 5 mM, Hepes 10 mM, EGTA 1 mM, NP40 0.2%, PMSF 0.2 mM, Protinin 0.2 TIU/ml, pepstatin 0.7 g/l, leupeptin 1 g/l, Na 3 VO 4 2 mM, NaF 6 mM. After incubation on ice for 5-10 min, extracts were centrifuged at 15 000 g for 10 min, and aliquots of supernatants were taken for protein quantitation.
One hundred micrograms of protein in the extract were used for immunoprecipitation. Reaction volumes were normalized to 0.1 ml with lysis buffer prior to the addition of antibody. For immunoprecipitation reactions, samples were incubated with primary antibody (anti-cdc2 monoclonal antibody; Pharmingen, San Diego, CA, USA) overnight. Precipitation of the antibody-antigen complex was accomplished by rotation for 3 h in the presence of protein A beads (Santa Cruz, Santa Cruz, CA, USA). Beads were washed twice in wash buffer A (lysis buffer without NP40), and twice in wash buffer B (TrisHCl 50 mM, EGTA 5 mM, Na 3 VO 4 1 mM, DTT 1 mM). After washing, buffer was removed carefully, and 10 l of assay dilution buffer (CDK Kinase Activity Kit; Upstate Biotechnology, Lake Placid, NY, USA) was immediately added to the beads. To this mixture 10 l each of substrate cocktail, cold ATP-
32P
ATP mix and inhibitory cocktail were added. The reaction was allowed to proceed for 10 min at 30°C with gentle shaking. A 25 l aliquot was then blotted on a square of p81 paper, washed three times with 75% phosphoric acid, and once with acetone. Washed squares were added to 1 ml scintillation cocktail fluid and read in a scintillation counter. Alternatively, the entire reaction may be loaded and run on SDS-PAGE and quantitated by phosphorimager analysis as well as gel scanning and densitometric measurements.
Detection of internucleosomal fragmentation of genomic DNA by agarose gel electrophoresis
After incubations with the designated concentrations and schedules of the drugs, 1 × 10 6 cells were pelleted. The genomic DNA was extracted and purified, and its purity was determined spectrophotometrically. 24 Agarose gel electrophoresis of 1.0 g of DNA was performed as described previously. 24 
Flow cytometric analysis of cell-cycle status and apoptosis
Untreated, thymidine-synchronized (vide infra) and Taxoltreated cells were washed and fixed in 70% ethanol, as described previously. 11 The flow cytometric evaluation of the cell-cycle status and apoptosis was performed by a method previously reported. 11 
Morphology of apoptotic cells
After treatment with or without drug, 50 × 10 3 cells were washed with PBS (pH 7.3) and resuspended in the same buffer. Cytospin preparations of the cell suspensions were fixed and stained with Wright stain. Cell morphology was determined by light microscopy. In all, five different fields were randomly selected for counting of at least 500 cells. The percentage of apoptotic cells was calculated for each experiment, as previously described. 24 
Statistical analysis
Significant differences between values obtained in a population of leukemic cells treated with different experimental conditions were determined by paired t-test analyses. A oneway ANOVA was also applied to the results of the various treatment groups, and post hoc analysis was performed using the Bonferroni correction method.
Results
Taxol promotes earlier peak in histone H1 kinase activity of CDK1
To determine the effect of clinically relevant concentrations of Taxol on CDK1 levels and its histone H1 kinase activity, the control HL-60/neo and HL-60/Bcl-x L cells were synchronized in S phase by treatment with 2.0 mM thymidine for 12 h, and then washed free of the drug. Flow cytometric evaluation revealed that at least 80% of cells were synchronized in S phase (data not shown). Subsequently, cells were untreated or treated with clinically relevant concentration of 500 nM Taxol. Aliquots of cells were harvested from 1 to 18 h, and CDK1 immunoprecipitates were assayed for in vitro histone H1 kinase activity. Figure 1 is representative of three separate experiments, and demonstrates that the kinase activity progressively increased in the untreated HL-60/neo cells from 3 to 7 h, peaking at four times the baseline level. A decline to baseline from peak levels of activity occurred after 10 h. In Taxoltreated HL-60/neo cells, a four-fold increase over the baseline levels of the kinase activity was evident earlier at 5 h. The kinase activity returned to the baseline levels after 10 h. In the untreated HL-60/Bcl-x L cells, the increase in the kinase activity was similar to HL-60/neo cells, and it peaked at 7 h. Following exposure of HL-60/Bcl-x L cells to Taxol, the total increase in the kinase activity was not different from the untreated HL-60/neo and HL-60/Bcl-x L cells. Similar to Taxoltreated HL-60/neo cells, in HL-60/Bcl-x L cells an earlier increase in the kinase activity was observed at 5 h, but the peak in the kinase activity was delayed. It is noteworthy that the total CDK1 levels remained unaltered and were not significantly different among untreated and Taxol-treated HL-60/neo vs HL-60/Bcl-x L cells. Taxol 
Cyclin B1 accumulation, tyrosine dephosphorylation of CDK1 and mitotic arrest is similar but apoptosis is inhibited in
Figure 2
Following release from synchronization in S phase, aliquots of cells were harvested after the indicated hours in the drugfree culture medium. Antiphosphotyrosine and cyclin B1 immunoblot analyses were performed. Both HL-60/neo and HL-60/Bcl-x L cells demonstrated CDK1 tyrosine dephosphorylation at 10 h and cyclin B1 accumulation and decline after 10 h, although CDK1 dephosphorylation was less complete in HL-60/Bcl-x L as compared to HL-60/neo cells.
Figure 3
Following release from synchronization in S phase, HL-60/neo and HL-60/Bcl-x L cells were exposed to 500 nM Taxol for up to 18 h. Aliquots of cells were harvested after the indicated hours of Taxol treatment. Antiphosphotyrosine and cyclin B1 immunoblot analyses as well as morphologic evaluation of apoptosis were performed. In HL-60/Bcl-x L cells, while Taxol-induced CDK1 tyrosine dephosphorylation at 10 h, cyclin B1 accumulation and decline after 10 h, and mitotic arrest were similar to HL-60/neo cells, Taxolinduced apoptosis was significantly inhibited (P Ͻ 0.001).
( Figures 2 and 3) . However, as also previously reported, 11 morphologically recognizable mitosis was not significantly different at 12 h in HL-60/neo and HL-60/Bcl-x L cells (P Ͼ 0.05) (panels c and f). This was confirmed by flow cytometric estimation of the percentage of cells in the G2/M phase of the cell cycle and also reported previously. 11 However at 16 h, a significantly higher mean percentage of Taxol-treated HL-60/neo cells exhibited the morphologic features of apoptosis: HL-60/neo, 32% vs HL-60/Bcl-x L 2% (P Ͻ 0.001). These data indicate that, in the synchronized HL-60 cells, Taxol-induced CDK1 activation and mitotic arrest precede the onset of the morphologic features of apoptosis. Taken together with the data presented above which demonstrate similar peak levels of the histone H1 kinase activity, Taxol-mediated activation of CDK1-cyclin B complex and mitotic arrest are unaffected by high Bcl-x L levels.
Taxol-induced CDK1 activity precedes caspase-3 activation and DNA fragmentation and apoptosis
In previous reports, we had also demonstrated that cleavage and activity of caspase-3 followed Taxol-induced mitotic arrest of HL-60 cells. 11, 13 In the present studies, we determined the effect of caspase inhibitor Ac-YVAD-cmk (600 M) on CDK1 kinase activity and mitotic arrest of HL-60 cells. Following S-phase synchronization, aliquots of untreated cells or cells treated with Taxol and/or Ac-YVAD-cmk were harvested at various times. In an alternative set of experiments, Ac-YVAD-cmk was substituted by zVAD-fmk (50 M). Immunoprecipitates of CDK1 were evaluated for their in vitro histone H1 kinase activity. As compared to the untreated control cells, after a 4-h exposure to Taxol (500 nM) a significant increase in the H1 kinase activity of CDK1 was observed (Figure 4 ,
Figure 4
CDK1 kinase activity induced by Taxol is not inhibited by the caspase inhibitor Ac-YVAD-cmk in HL-60/neo cells. Following release from S phase synchronization, HL-60/neo cells were exposed to Taxol (500 nM) and/or Ac-YVAD-cmk (600 M). After the indicated time-intervals, immunoprecipitates of CDK1 were evaluated for the histone HI kinase activity of CDK1, as described in the text. Co-treatment with Ac-YVAD-cmk did not inhibit Taxol-mediated increase in the histone H1 kinase activity of CDK1. Following release from S phase synchronization, HL-60/neo and HL-60/Bcl-x L cells were exposed to 500 nM Taxol. From aliquots of cells harvested at various time-intervals, S-100 cytosolic fractions were extracted and immunoblot analysis of cyt c was performed. Up to 10 h of exposure to Taxol did not produce a significant accumulation of cytosolic cyt c in HL-60/neo cells (data not shown). However, by 12 h of Taxol exposure a six-fold increase in the baseline levels of cytosolic cyt c was observed ( Figure 5, panel a) . These levels did not increase with further exposure to Taxol (not shown). Taxolinduced accumulation of cytosolic cyt c was blocked in HL-60/Bcl-x L cells ( Figure 5, panel a) . As also previously reported, 11 Taxol-induced p32 pro-caspase-3 (labeled as caspase-3) cleavage (panel b), PARP degradation (panel c), and internucleosomal DNA fragmentation (panel d) were also blocked in HL-60/Bcl-x L cells. Co-treatment of HL-60/neo cells with Ac-YVAD-cmk significantly inhibited Taxolinduced p32 pro-caspase-3 cleavage and down-regulation as well as the ensuing molecular events, 11 without affecting the cytosolic increase of cyt c (not shown). Similar effects were observed following co-treatment with zVAD-fmk (data not shown). By demonstrating that Bcl-x L overexpression blocks Taxol-induced cyt c accumulation in the cytosol and, similar to caspase inhibitors, blocks caspase activity but not the CDK1 activation and mitosis, collectively these data show that Taxol-induced CDK1 activity may precede and be upstream to the pre-apoptotic molecular events that produce cleavage and activity of caspases and apoptosis.
Discussion
Since the activation of CDK1 is responsible for the G2/M transition, and premature or unscheduled CDK1 activity has been linked to apoptosis, 8, 19 in the present studies we determined the temporal relationship of Taxol-induced CDK1 activation and mitosis to the recently elucidated cytosolic events that trigger the molecular cascade of apoptosis. Data from cells synchronously released from S phase and exposed to Taxol clearly demonstrate that Taxol promotes the accumulation of cyclin B1 and induces the in vitro histone H1 kinase activity of CDK1, which triggers G2/M transition. In these cells, the tyrosine dephosphorylation of CDK1 also precedes Taxolinduced mitosis and the morphologic features of apoptosis. Taxol-induced histone kinase activity of CDK1 appears to precede its tyrosine dephosphorylation (Figure 2 vs Figure 3 ). However, this may be because these two parameters were measured in separate sets of experiments on the synchronized HL-60/neo and HL-60/Bcl-x L cells. Data presented here also demonstrate for the first time that following exposure of the synchronized cells to Taxol, a significant increase in the cytosolic cyt c occurs after 10 h, without further accumulation after 12 h. This cytosolic accumulation of cyt c coincides with the decline in the levels of pro-caspase-3 and generation of the PARP cleavage activity of caspase-3 ( Figure 5 ). Collectively, these findings suggest that Taxol-induced molecular events related to the G2/M transition temporally precede caspase-3 activation and apoptosis.
Although it is clearly not the mediator of apoptosis due to all stimuli, previous reports have indicated that premature and unscheduled CDK1 activation can induce apoptosis in some settings. [19] [20] [21] For example, granzyme B has been shown to mediate apoptosis induced by cytotoxic T lymphocytes (CTL) by premature activation of CDK1, and its inactivation by phosphorylation inhibits granzyme B-induced apoptosis.
19 CDK1-dependence has also been shown for HIV-1 tat and anti-CD3-induced apoptosis. 20 In another report, the inhibition of CDK1 activity was demonstrated to prevent Fas-mediated apoptosis. 25 Activation of CDC25 phosphatase and, in turn CDK1 activation, has also been shown to mediate apoptosis due to novel anticancer agents. 26 Collectively, these reports highlight CDK1 activation as one of the important upstream molecular events triggering the apoptotic cascade. This cascade involves the mitochondrial permeability transition and release of cyt c into the cytosol. 14, 27 Here, cyt c binds to APAF-1. 28 In the presence of dATP and cyt c, APAF-1 binds and activates caspase-9 by cleavage, which in turn brings about the cleavage and activity of caspase-3. 29 In the present studies we have demonstrated that a 12-h treatment with Taxol causes significant and maximal increase in the cytosolic cyt c, where it promotes the cleavage and PARP degradation activity of caspase-3. However, the precise mechanism by which Taxolinduced CDK1 activation and G2/M transition cause the efflux of cyt c from mitochondria and its accumulation in the cytosol remains to be elucidated. Overexpression of Bcl-x L blocks Taxol-induced cytosolic accumulation of cyt c and the resulting cleavage and activity of caspase-3. In contrast, the tetrapeptide caspase inhibitors and zVAD-fmk have no effect on Taxol-induced increase in cytosolic cyt c, but inhibit the ensuing caspase-3 cleavage and activity. 14, 15 The inability of caspase inhibitors to block the efflux of cyt c from mitochondria due to other apoptotic stimuli has also been reported previously. 15 Since the effects of Bcl-x L and the caspase inhibitors on caspase-3 activity occur without any significant inhibition of Taxol-induced CDK1 activity and G2/M transition, our data also support the findings cited above, [19] [20] [21] which describe unscheduled CDK1 activation as preceding the execution of apoptosis triggered by a number of stimuli.
Recently, Taxol and a number of other anti-microtubule anticancer agents have been shown to induce serine phosphorylation of Bcl-2, which is associated with the abrogation of its antiapoptotic activity. [30] [31] [32] Taxol-induced Bcl-2 phosphorylation has also been demonstrated as increasing the intracellular ratio of free to bound Bax. 13 Whether Taxolinduced serine phosphorylation of Bcl-2 in its 'loop' domain affects its membrane channel protein function, 33 by which Bcl-2 may be regulating the mitochondrial permeability transition and the release of cyt c into the cytosol, has not been firmly established. [16] [17] [18] 34 In contrast, another report has suggested that phosphorylation of Bcl-2 may be required for its antiapoptotic function. 35 Notwithstanding this controversy, Taxol-induced antimicrotubule effects and CDK1-mediated G2/M transition appear to be linked to the induction of Bcl-2 phosphorylation. 13, 36, 37 This, again, suggests that Taxolinduced antimicrotubule effects and cell-cycle perturbations temporally precede and may be mechanistically related to the molecular cascade of apoptosis triggered by caspase-3 activity and its regulation by the Bcl-2 family of proteins. Taken together with our findings presented in this and previous reports, 11, 13 a clearer picture of the hierarchy or molecular ordering of Taxol-induced events has emerged, starting with the inhibition of microtubule dynamics that is associated with CDK1 activity and Bcl-2 phosphorylation, followed by the cytosolic cyt c-mediated caspase-3 activation and apoptosis.
